Chimeric Antigen Receptor T-cell Therapy, Hematological Malignancies
Conditions
Keywords
gut microbiota, CAR-T
Brief summary
The purpose of this prospective and observational study is to evaluate the correlation between gut microbiota and clinical response to CAR-T treatment for hematological malignancies
Detailed description
Chimeric antigen receptor T-cell (CAR-T) therapy has shown impressive efficacy in hematological malignancies. However, response rates and associated immune-related adverse effects widely vary among patients. And no biomarkers have been identified to predict the efficacy and associated toxicities after CAR-T therapy in patients. Several preclinical experiments and clinical studies have shown that gut microbiota was associated with the efficacy of T cell-driven cancer immunotherapies and their toxicities. In hematologic malignancies, gut microbiota was associated with the development of graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, the potential correlation between gut microbiota and the effificacy and toxicity of CAR-T therapy is unclear. Therefore, in this study, we aim to evaluate the correlation between gut microbiota and clinical response to CAR-T treatment for hematological malignancies.
Interventions
None listed
Sponsors
The First Affiliated Hospital of Soochow University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
16 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. Age 16-65 years. 2. Hematologic malignancies intended for CAR-T therapy. 3. Expected survival time ≥ 3 months (according to investigator's judgement). 4. Left ventricular ejection fractions ≥ 55% by echocardiography. 5. ALT / AST \<3 times of normal amounts. 6. Creatinine\<2.0mg/dl. 7. PT and APPT \<2 times of normal amounts. 8. Karnofsky performance status ≥ 60. 9. The ECOG score ≤2 points.
Exclusion criteria
1. Pregnant (or lactating) women; 2. Uncontrolled active infection； 3. Active infection of hepatitis B virus or hepatitis C virus； 4. Human immunodeficiency virus (HIV) positive； 5. Patients with a history of myocardial infarction or severe arrhythmia within six months or those with class III or IV cardiac function according to the New York classification； 6. Any situations that the investigator believes may increase the risk of patients or interfere with the results of study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| gut microbiota | From pre-lymphodepletion regimen to day 28 after CAR-T cells infusion | diversity and composition of the gut microbiota |
| efficacy of CAR-T therapy | six months | CR，PR and NR |
| toxicity of CAR-T therapy | six months | Adverse events are evaluated with CTCAE V5.0 |
Countries
China
Contacts
Primary ContactXiaowen Tang, PhD
Backup ContactDepei Wu, PhD
Outcome results
None listed